Roche considering selling drugs directly to US patients, CEO says

Roche is considering implementing a direct-to-consumer (DTC) sales model for its prescription medicines in the U.S., aiming to reduce patient costs by bypassing pharmacy benefit managers (PBMs) amid U.S. government pressure on drug pricing. This potential shift, which CEO Thomas Schinecker suggests would cut out middlemen, follows similar moves by Bristol Myers, Pfizer, Eli Lilly, and Novo Nordisk for specific drugs. Such a model could significantly disrupt the traditional U.S. drug distribution landscape, offering competitive cash prices that may appeal to both uninsured and insured patients seeking alternatives to insurer-negotiated rates.

Analysis

Roche is actively considering a strategic shift to a direct-to-consumer (DTC) sales model for its prescription medicines in the U.S., a move aimed at mitigating government pricing pressure and reducing patient costs by circumventing pharmacy benefit managers (PBMs). This potential strategy follows established precedents from peers like Bristol Myers, Pfizer, Eli Lilly, and Novo Nordisk, who have already launched DTC channels for blockbuster drugs such as Eliquis and Wegovy. While CEO Thomas Schinecker suggested the model could apply across Roche's entire portfolio, industry sources indicate that small-molecule drugs are the most viable candidates due to simpler distribution logistics. This initiative could disrupt the traditional U.S. pharmaceutical value chain by creating a competitive cash-price channel that appeals not only to the uninsured but also to insured patients with high co-pays. The consideration of this model, alongside Roche's planned $50 billion investment in the U.S. and increased inventory to hedge against tariffs, signals a multifaceted strategy to navigate a challenging regulatory and political landscape while reinforcing its market presence.

Key Decisions for Investors

• For investors in Roche (ROG.S), this potential DTC strategy is a proactive measure against U.S. pricing pressure that could defend or enhance margins, but its financial impact hinges on which specific drugs are included and the model's logistical execution.
• The accelerating adoption of DTC models by major pharmaceutical firms represents a significant, long-term secular headwind for Pharmacy Benefit Managers (PBMs) and traditional drug distributors, warranting a review of exposure to these intermediaries.
• Investors should monitor the broader pharmaceutical sector to identify which companies, particularly those with high-volume, small-molecule drugs like Eli Lilly and Novo Nordisk, are best positioned to successfully implement and scale a DTC strategy.
• The initiative's success is closely tied to the U.S. political and regulatory environment, meaning investors must consider the risk that future administrative policies on drug pricing could either accelerate or impede this industry-wide shift.